Online citations, reference lists, and bibliographies.
← Back to Search

Role Of 18F-FDG PET For Evaluating Malignant Pleural Mesothelioma.

C. Nanni, P. Castellucci, M. Farsad, C. Pinto, A. Moretti, C. Pettinato, M. Marengo, S. Boschi, R. Franchi, A. Martoni, N. Monetti, S. Fanti
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Malignant Pleural Mesothelioma (MPM) is a relatively rare neoplasia characterized by a poor prognosis. Recent studies show that new therapeutic approaches can lead to an improvement in life quality and to a prolonged survival; therefore, proper evaluation of MPM before, as well as after, therapy, is needed. The aim of this study was to evaluate the impact of 18F-FDG photon emission tomography (PET) scan compared to computed tomography (CT) findings in patients affected by MPM, whether untreated or already treated. We studied 15 consecutive patients (13 male and 2 female) with a histological diagnosis of MPM, with a mean age of 69.9 years (range: 38-78 years old) and a recent total-body CT scan. Five (5) patients were studied for staging, while 10 patients were studied after therapy. An FDG PET scan was carried out 60 minutes after an intravenous (i.v.) injection of 370 MBq of 18F-FDG. For each patient, we compared the PET stage to the CT stage, and evaluated the role of PET in choosing a therapeutic approach. In 9 of 15 (60%) patients, there was no difference between the PET and the CT stage. In 2 of 15 (13%) patients, PET upstaged the disease, while in 4 of 15 (27%) patients PET downstaged MPM. According to these results, patient management was changed in 3 cases. Specifically, 1 patient was excluded from surgery, and 2 patients had different chemotherapy. These data suggest that PET is useful in the evaluation of MPM, giving additional data that can clarify doubtful CT findings, especially regarding lymph node involvement and distant lesions. In conclusion, FDG PET was found to play a worth-while role in patient management.
This paper references

This paper is referenced by
Current state and future directions of pleural mesothelioma imaging.
S. Armato (2008)
New agents in the management of advanced mesothelioma.
N. Vogelzang (2005)
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma
K. Kitajima (2016)
Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer.
A. Mavi (2005)
Long-term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase/Ganciclovir Suicide Gene Therapy
D. Sterman (2005)
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
Diagnostic Imaging of Lung and Pleural Tumors
P. Groot (2013)
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
V. Pinelli (2015)
Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations.
M. Truong (2013)
Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease
A. Mavi (2009)
PET evaluation of lung cancer.
Tira Bunyaviroch (2006)
The Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Mesothelioma
Ö. Özmen (2018)
Preoperative Evaluation of Patients With Malignant Pleural Mesothelioma: Role of Integrated CT-PET Imaging
M. Truong (2006)
What is the best way to diagnose and stage malignant pleural mesothelioma?
I. Zahid (2011)
2.1 Quels critres diagnostiques pour le msothliome pleural malin (MPM)
P. Astoul (2006)
Diseases of the Pleura and the Chest Wall
Claus Peter Heussel (2009)
Current chemotherapeutic treatment of malignant pleural mesothelioma
A. Nowak (2004)
1 – Imaging Tumors of the Lung and Pleura
E. Marom (2010)
La TEP dans les cancers bronchopulmonaires ou pleuraux primitifs
J. Talbot (2006)
Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results
C. Plathow (2008)
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
V. Ambrosini (2005)
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
S. Sharif (2011)
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
PET: other thoracic malignancies
L. Quint (2006)
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
Z. Celen (2011)
Chapter 8 – Pleural Tumors
M. Truong (2012)
Response evaluation in mesothelioma: Beyond RECIST.
Lin Cheng (2015)
Positron Emission Tomography in Mesothelioma Patients
G. Grassetto (2009)
Best evidence topic - Thoracic oncologic Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sumera Sharif (2011)
Semantic Scholar Logo Some data provided by SemanticScholar